Abstracts tagged "Clinical trials and fibromyalgia"

Abstract Number: 46 • 2016 ACR/ARHP Annual Meeting
Novel Composite Responder Endpoints for Fibromyalgia Therapy Assessment
R Michael Gendreau¹, Lesley Arnold², Daniel J. Clauw³, Judith Gendreau⁴, Bruce Daugherty⁴ and Seth Lederman⁴, ¹Gendreau Consulting LLC, Poway, CA, ²University of Cincinnati, Cincinnati, OH, ³Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁴Tonix Pharmaceuticals, New York, NY
Background/Purpose: Novel composite responder definitions for fibromyalgia (FM) clinical trials have been proposed by the Outcome Measures in Rheumatology (OMERACT) FM subcommittee. These definitions which…
Abstract Number: 1861 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Japanese Patients with Fibromyalgia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase III Trial and Open-Label Extension Study
Hiroyoshi Ohta¹, Masayuki Ohkura¹, Makoto Suzuki¹, Hiroshi Oka², Chie Usui³ and Kusuki Nishioka⁴, ¹Pfizer Japan Inc, Tokyo, Japan, ²Rheumatic Disease Center, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, ³Department of Psychiatry, Juntendo University School of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan, ⁴Institute of Innovative Medical Science and Education, Tokyo Medical University, Tokyo, Japan
Background/Purpose: Fibromyalgia (FM) is a common, chronic pain disorder, however, at the time of this study there was no approved medicine for FM patients in…
Abstract Number: 1872 • 2012 ACR/ARHP Annual Meeting
Quality of Reporting in Pharmacological Randomized Controlled Trials for Fibromyalgia
Karen Yeter¹, Winnie Pang², Nasim A. Khan³ and Karina D. Torralba², ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for assessment of healthcare interventions. Recently, there have been growing concerns about the quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].